Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Palmitoylethanolamide (PEA) is an endogenous fatty acid amide that has garnered attention for its anti-inflammatory, analgesic, and neuroprotective properties. The rationale for its use in psoriasis hinges on its ability to modulate immune responses and downregulate mast cell activation, both of which play a role in psoriatic inflammation. Several preclinical studies have demonstrated that PEA can decrease the production of pro-inflammatory cytokines and reduce skin inflammation in animal models.

Clinical evidence is limited but emerging. A small number of clinical trials and case reports have investigated topical formulations of PEA in psoriasis, often as a component of emollient or anti-itch creams. For instance, a few open-label studies have reported improvements in itch intensity and skin scaling in patients with mild-to-moderate psoriasis using PEA-containing creams. However, these studies are generally of low quality, with small sample sizes, lack of blinding, and short durations. Systematic reviews and meta-analyses of PEA for dermatological conditions highlight the need for larger, high-quality randomized controlled trials to confirm efficacy in psoriasis specifically.

In summary, while there is a plausible scientific mechanism and some preliminary clinical evidence supporting the use of PEA in psoriasis, the overall strength of evidence is weak (rated 2/5). It should be considered experimental and not a mainstay of psoriasis management until more robust data are available.

More about Palmitoylethanolamide (PEA)
More about Psoriasis

Other ingredients used for Psoriasis

Other health conditions supported by Palmitoylethanolamide (PEA)

Products containing Palmitoylethanolamide (PEA)